$0.66 EPS Expected for Valeant Pharmaceuticals International, Inc. (VRX) as of May, 8

April 17, 2018 - By Benjamin Allen

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Corporate Logo
Big Money Sentiment decreased to 0.97 in Q4 2017. It has change of 0.02, from 2017Q3’s 0.99. The ratio fall due to Valeant Pharmaceuticals International, Inc. positioning: 51 sold and 74 reduced. 54 funds bought stakes and 67 increased stakes. Investors holded 169.87 million in 2017Q3 but now own 169.66 million shares or 0.12% less.
Hexavest holds 0.13% or 545,703 shs. Prudential Public Ltd Com invested in 0.02% or 290,714 shs. Moreover, Winfield Assoc has 0% invested in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) for 55 shs. The Illinois-based Grp One Trading L P has invested 0.14% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Tb Alternative Assets has 0.4% invested in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Aviva Public Limited Company stated it has 0.02% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Clinton Group Inc Inc stated it has 0.18% of its capital in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Marshall Wace Llp stated it has 0.13% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Sivik Global Ltd Company holds 100,000 shs or 0.77% of its capital. Scotia Cap reported 131,117 shs stake. Pacad Ltd has invested 0.09% of its capital in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Nine Masts Cap accumulated 166 shs. Shell Asset Company has 0.01% invested in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). 246,500 are owned by Stanley Cap Mgmt. Twin Tree Lp accumulated 4,100 shs or 0% of the stock.

Valeant Pharmaceuticals International, Inc. had 0 insider sales and 3 insider purchases since March 8, 2018. This’s net activity of $876,370. 10,000 shs were bought by DE SCHUTTER RICHARD U, worth $153,400. On Tuesday, March 13 the insider Herendeen Paul bought $241,470.

On May, 8 Valeant Pharmaceuticals International, Inc. (NYSE:VRX)’s earnings report is anticipated by WallStreet, Zacks reports. Analysts have expectation on stock’s earnings per share of $0.66. That’s down 76.43 % from last year’s $2.8 earnings per share. In case of $0.66 earnings per share VRX’s profit could reach $230.25M. Analysts at Wall Street see Valeant Pharmaceuticals International, Inc.’s -32.65 % negative EPS growth compared to $0.98 earnings per share for last quarter. VRX reached $17.23 on during the last trading session after $0.08 change.Currently Valeant Pharmaceuticals International, Inc. is uptrending after 42.00% change in last April 17, 2017. VRX has 6.27M shares volume. VRX outperformed by 30.45% the S&P500.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Ratings Coverage

In total 14 analysts cover Valeant Pharma (NYSE:VRX). “Buy” rating has 2, “Sell” are 4, while 8 are “Hold”. 14% are bullish. 29 are the (NYSE:VRX)’s analyst reports since October 20, 2017 according to StockzIntelligence Inc. In Friday, December 15 report Mizuho maintained it with “Underperform” rating and $10 target. On Friday, April 6 the stock of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) earned “Hold” rating by Mizuho. On Friday, October 20 the firm earned “Sell” rating by Piper Jaffray. On Thursday, December 14 the stock of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) earned “Underweight” rating by JP Morgan. In Monday, December 4 report BTIG Research maintained the stock with “Hold” rating. On Monday, November 6 the firm has “Hold” rating given by Canaccord Genuity. On Wednesday, February 28 the firm has “Buy” rating by Cantor Fitzgerald given. On Thursday, November 9 the stock of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) earned “Hold” rating by H.C. Wainwright. On Wednesday, November 1 Mizuho maintained the shares of VRX in report with “Sell” rating. The stock rating was downgraded by J.P. Morgan to “Sell” on Thursday, December 14.

Valeant Pharmaceuticals International, Inc. operates as a pharmaceutical and medical device firm worldwide.The firm is worth $6.01 billion. It operates in three divisions: Bausch + Lomb/International, Branded Rx, and U.S.The P/E ratio is 2.52. Diversified Products.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.